State Of Tennessee, Treasury Department Uni Qure N.V. Transaction History

State Of Tennessee, Treasury Department

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 15, 2023	BUY	$11.12 - $22.2 $12,543 - $25,041	1,128 Added 4.63%	25,483 $292,000
Q1 2023 May 12, 2023	SELL	$18.7 - $23.07 $59,073 - $72,878	-3,159 Reduced 11.48%	24,355 $490,000
Q4 2022 Feb 15, 2023	BUY	$18.12 - $27.32 $29,698 - $44,777	1,639 Added 6.33%	27,514 $623,000
Q3 2022 Jan 26, 2023	BUY	$16.98 - $25.54 $25,962 - $39,050	1,529 Added 6.28%	25,875 $486,000
Q2 2022 Aug 15, 2022	SELL	$13.15 - $20.45 $2,643 - $4,110	-201 Reduced 0.82%	24,346 $454,000
Q1 2022 May 11, 2022	BUY	$14.54 - $21.5 $27,146 - $40,140	1,867 Added 8.23%	24,547 $443,000
Q4 2021 Feb 15, 2022	BUY	$20.24 - $36.01 $42,504 - $75,621	2,100 Added 10.2%	22,680 $470,000
Q3 2021 Nov 12, 2021	BUY	$26.01 - $38.22 $535,285 - $786,567	20,580 New	20,580 $660,000

142

35.3M

1.54M

389K

Ticker QURE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,729,100
Market Cap $300M
Description
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...

Get notified when there are updates to the investment portfolio of State Of Tennessee, Treasury Department, based on Form 13F filings with the SEC.

Stay updated on State Of Tennessee, Treasury Department with notifications on news.